Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 12 | 2013 | 546 | 2.890 |
Why?
|
| Biomarkers, Tumor | 8 | 2013 | 1464 | 1.200 |
Why?
|
| Diagnosis, Differential | 14 | 2022 | 1565 | 0.930 |
Why?
|
| Neurothekeoma | 2 | 2012 | 5 | 0.840 |
Why?
|
| Chancre | 1 | 2020 | 2 | 0.770 |
Why?
|
| Syphilis, Cutaneous | 1 | 2020 | 3 | 0.770 |
Why?
|
| Treponema pallidum | 1 | 2020 | 8 | 0.770 |
Why?
|
| Skin Diseases | 2 | 2012 | 166 | 0.760 |
Why?
|
| Mouth Mucosa | 1 | 2020 | 67 | 0.740 |
Why?
|
| Rectum | 1 | 2020 | 146 | 0.710 |
Why?
|
| Skin | 2 | 2020 | 554 | 0.690 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2019 | 6 | 0.690 |
Why?
|
| Conjunctival Diseases | 1 | 2018 | 7 | 0.680 |
Why?
|
| Immunohistochemistry | 9 | 2019 | 1753 | 0.680 |
Why?
|
| Genes, Retinoblastoma | 1 | 2018 | 22 | 0.670 |
Why?
|
| Hernia | 1 | 2018 | 23 | 0.670 |
Why?
|
| Orbital Diseases | 1 | 2018 | 21 | 0.660 |
Why?
|
| Drug Eruptions | 1 | 2018 | 35 | 0.630 |
Why?
|
| Adipose Tissue | 1 | 2018 | 240 | 0.560 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 185 | 0.540 |
Why?
|
| Penile Neoplasms | 2 | 2022 | 10 | 0.530 |
Why?
|
| Sarcoma | 2 | 2007 | 215 | 0.530 |
Why?
|
| Receptors, IgE | 1 | 2015 | 7 | 0.530 |
Why?
|
| Urticaria | 1 | 2015 | 10 | 0.530 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 797 | 0.530 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2015 | 44 | 0.520 |
Why?
|
| Histiocytoma, Benign Fibrous | 2 | 2011 | 25 | 0.490 |
Why?
|
| Autoantibodies | 1 | 2015 | 267 | 0.470 |
Why?
|
| Meningioma | 1 | 2013 | 60 | 0.450 |
Why?
|
| Middle Aged | 17 | 2022 | 25028 | 0.450 |
Why?
|
| Handwriting | 1 | 2012 | 6 | 0.440 |
Why?
|
| Medical Audit | 1 | 2012 | 41 | 0.430 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2012 | 10 | 0.430 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 138 | 0.430 |
Why?
|
| Aged | 15 | 2022 | 18415 | 0.430 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2012 | 14 | 0.430 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 1376 | 0.410 |
Why?
|
| DNA, Viral | 1 | 2012 | 265 | 0.410 |
Why?
|
| Indoles | 1 | 2013 | 318 | 0.400 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 279 | 0.400 |
Why?
|
| Lipoma | 1 | 2011 | 25 | 0.400 |
Why?
|
| Bowen's Disease | 1 | 2011 | 9 | 0.400 |
Why?
|
| Paget Disease, Extramammary | 1 | 2011 | 8 | 0.400 |
Why?
|
| Sulfonamides | 1 | 2013 | 300 | 0.400 |
Why?
|
| Alopecia | 2 | 2021 | 34 | 0.390 |
Why?
|
| Herpes Simplex | 1 | 2012 | 202 | 0.390 |
Why?
|
| Male | 18 | 2022 | 40965 | 0.380 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 252 | 0.380 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2011 | 57 | 0.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 1197 | 0.380 |
Why?
|
| Carcinoma in Situ | 1 | 2011 | 53 | 0.380 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2010 | 17 | 0.370 |
Why?
|
| Female | 18 | 2021 | 44532 | 0.370 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 6509 | 0.360 |
Why?
|
| Angiolymphoid Hyperplasia with Eosinophilia | 1 | 2009 | 3 | 0.360 |
Why?
|
| Collagen | 1 | 2011 | 269 | 0.360 |
Why?
|
| Leiomyoma | 1 | 2013 | 191 | 0.350 |
Why?
|
| Humans | 27 | 2022 | 86643 | 0.350 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2010 | 127 | 0.340 |
Why?
|
| Arm | 1 | 2009 | 91 | 0.340 |
Why?
|
| Melanoma | 1 | 2013 | 459 | 0.340 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2010 | 118 | 0.340 |
Why?
|
| Electronic Health Records | 1 | 2012 | 319 | 0.340 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2008 | 2 | 0.330 |
Why?
|
| Glomus Tumor | 1 | 2008 | 8 | 0.330 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2008 | 28 | 0.330 |
Why?
|
| Nipples | 1 | 2008 | 37 | 0.320 |
Why?
|
| Leg | 1 | 2008 | 137 | 0.320 |
Why?
|
| Adult | 11 | 2022 | 25648 | 0.310 |
Why?
|
| Neoplasms, Bone Tissue | 1 | 2007 | 2 | 0.310 |
Why?
|
| Buttocks | 1 | 2007 | 10 | 0.300 |
Why?
|
| Leiomyosarcoma | 1 | 2007 | 40 | 0.300 |
Why?
|
| CD56 Antigen | 1 | 2007 | 18 | 0.300 |
Why?
|
| Fibroma | 1 | 2007 | 33 | 0.300 |
Why?
|
| CD4 Antigens | 1 | 2007 | 83 | 0.300 |
Why?
|
| Leukemia, Myeloid | 1 | 2008 | 249 | 0.290 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2010 | 426 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2006 | 10 | 0.280 |
Why?
|
| Transcription Factors | 1 | 2013 | 1565 | 0.270 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 621 | 0.260 |
Why?
|
| Biopsy | 3 | 2020 | 1163 | 0.250 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 329 | 0.230 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2022 | 4 | 0.220 |
Why?
|
| Vascular Neoplasms | 1 | 2022 | 19 | 0.220 |
Why?
|
| Young Adult | 4 | 2022 | 5976 | 0.200 |
Why?
|
| Ustekinumab | 1 | 2021 | 47 | 0.200 |
Why?
|
| Child | 3 | 2019 | 6927 | 0.170 |
Why?
|
| Illinois | 1 | 2020 | 462 | 0.170 |
Why?
|
| Sampling Studies | 1 | 2018 | 70 | 0.170 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2018 | 25 | 0.170 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 1169 | 0.160 |
Why?
|
| Lichenoid Eruptions | 1 | 2018 | 3 | 0.160 |
Why?
|
| Psoriasis | 1 | 2021 | 240 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 231 | 0.160 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 235 | 0.160 |
Why?
|
| Granuloma | 1 | 2018 | 65 | 0.160 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 129 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 159 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 927 | 0.140 |
Why?
|
| Neoplasm Proteins | 2 | 2010 | 532 | 0.140 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 456 | 0.140 |
Why?
|
| Lichen Planus | 1 | 2015 | 10 | 0.140 |
Why?
|
| Glioblastoma | 1 | 2018 | 255 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1673 | 0.140 |
Why?
|
| Scalp | 1 | 2015 | 72 | 0.130 |
Why?
|
| Mast Cells | 1 | 2015 | 92 | 0.130 |
Why?
|
| Actins | 2 | 2008 | 451 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 1721 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 2903 | 0.120 |
Why?
|
| Eosinophils | 1 | 2015 | 194 | 0.120 |
Why?
|
| Neutrophils | 1 | 2015 | 307 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 241 | 0.110 |
Why?
|
| Chickenpox | 1 | 2012 | 39 | 0.110 |
Why?
|
| Adolescent | 3 | 2021 | 8981 | 0.110 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 43 | 0.110 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 339 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 763 | 0.110 |
Why?
|
| Herpes Zoster | 1 | 2012 | 78 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2013 | 276 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2015 | 971 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 273 | 0.100 |
Why?
|
| Simplexvirus | 1 | 2012 | 151 | 0.100 |
Why?
|
| PAX8 Transcription Factor | 1 | 2010 | 23 | 0.100 |
Why?
|
| Hypersensitivity | 1 | 2012 | 154 | 0.100 |
Why?
|
| Paired Box Transcription Factors | 1 | 2010 | 50 | 0.100 |
Why?
|
| Mucin-1 | 1 | 2010 | 44 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1920 | 0.090 |
Why?
|
| Ki-1 Antigen | 1 | 2009 | 17 | 0.090 |
Why?
|
| Antigens, CD34 | 1 | 2010 | 158 | 0.090 |
Why?
|
| Extracellular Matrix | 1 | 2011 | 232 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 107 | 0.090 |
Why?
|
| Collagen Type IV | 1 | 2008 | 24 | 0.080 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2008 | 11 | 0.080 |
Why?
|
| Muramidase | 1 | 2008 | 34 | 0.080 |
Why?
|
| Peroxidase | 1 | 2008 | 51 | 0.080 |
Why?
|
| Mitosis | 1 | 2008 | 153 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2008 | 281 | 0.080 |
Why?
|
| Ossification, Heterotopic | 1 | 2007 | 31 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 1056 | 0.070 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2006 | 21 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2008 | 579 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2008 | 458 | 0.070 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 1204 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2008 | 7993 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2012 | 3612 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2018 | 8489 | 0.060 |
Why?
|
| Prostatic Hyperplasia | 1 | 2006 | 88 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2010 | 1458 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2006 | 912 | 0.060 |
Why?
|
| Prostatectomy | 1 | 2006 | 471 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2009 | 1196 | 0.050 |
Why?
|
| Penis | 1 | 2022 | 57 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 1076 | 0.050 |
Why?
|
| Disease Progression | 1 | 2006 | 1531 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1991 | 0.050 |
Why?
|
| Pregnancy | 1 | 2008 | 2894 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 1939 | 0.050 |
Why?
|
| Prognosis | 1 | 2007 | 3679 | 0.040 |
Why?
|
| Extremities | 1 | 2015 | 167 | 0.030 |
Why?
|
| Keratins | 1 | 2009 | 63 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2009 | 50 | 0.020 |
Why?
|